Recent progress on nanoparticle-based drug delivery systems for cancer therapy - PubMed (original) (raw)
Recent progress on nanoparticle-based drug delivery systems for cancer therapy
Yanru Xin et al. Cancer Biol Med. 2017 Aug.
Abstract
The development of cancer nanotherapeutics has attracted great interest in the recent decade. Cancer nanotherapeutics have overcome several limitations of conventional therapies, such as nonspecific biodistribution, poor water solubility, and limited bioavailability. Nanoparticles with tuned size and surface characteristics are the key components of nanotherapeutics, and are designed to passively or actively deliver anti-cancer drugs to tumor cells. We provide an overview of nanoparticle-based drug delivery methods and cancer therapies based on tumor-targeting delivery strategies that have been developed in recent years.
Keywords: Nanoparticles; cancer therapy; drug delivery; nanomedicine; tumor targeting.
Figures
1
Schematic for the proposed in vivo behavior of DPHAIM. Reproduced with permission from Ref. .
2
Schematic of the temperature-switched Fe3O4@PNG-CD nanosystem for controlled drug release. Reproduced with permission from Ref. .
3
Scheme showing the effects of HAase on the modulation of the tumor microenvironment. By improving tumor oxygenation and promoting the EPR effect, HAase enhances the efficacy of in vivo PDT cancer treatment. Reproduced with permission from Ref. .
4
Schematic of the synthetic process of UCP@SiO2-NPs and UCP@SiO2-NRs and application in the PTT of oral cancer. Reproduced with permission from Ref. .
5
(A) Construction of the GNR-ACPI nanoplatform. (B) Dual-mode imaging and combined PTT/PDT therapy in vivo after the intravenous injection of GNR-ACPI. (B1) Accumulation of GNR-ACPI in the tumor site through the EPR effect. (B2) Enhanced internalization of activated CPP-PpIX by tumor cells via the help of CPP and triggered by the combination of PTT/PDT therapy upon laser irradiation. Reproduced with permission from Ref. .
6
Mechanism of anti-tumor immune responses induced by PLGA-ICG-R837-based PTT in combination with checkpoint-blockade. Reproduced with permission from Ref. .
Similar articles
- Therapeutic nanoparticles for drug delivery in cancer.
Cho K, Wang X, Nie S, Chen ZG, Shin DM. Cho K, et al. Clin Cancer Res. 2008 Mar 1;14(5):1310-6. doi: 10.1158/1078-0432.CCR-07-1441. Clin Cancer Res. 2008. PMID: 18316549 Review. - Nanoparticles as carriers for drug delivery in cancer.
Dadwal A, Baldi A, Kumar Narang R. Dadwal A, et al. Artif Cells Nanomed Biotechnol. 2018;46(sup2):295-305. doi: 10.1080/21691401.2018.1457039. Epub 2018 Jul 25. Artif Cells Nanomed Biotechnol. 2018. PMID: 30043651 Review. - Improved Targeting of Cancers with Nanotherapeutics.
Foster C, Watson A, Kaplinsky J, Kamaly N. Foster C, et al. Methods Mol Biol. 2017;1530:13-37. doi: 10.1007/978-1-4939-6646-2_2. Methods Mol Biol. 2017. PMID: 28150194 - Nanotherapeutics to overcome conventional cancer chemotherapy limitations.
Chidambaram M, Manavalan R, Kathiresan K. Chidambaram M, et al. J Pharm Pharm Sci. 2011;14(1):67-77. doi: 10.18433/j30c7d. J Pharm Pharm Sci. 2011. PMID: 21501554 Review. - Nanotherapeutics in oral and parenteral drug delivery: Key learnings and future outlooks as we think small.
Tyagi P, Subramony JA. Tyagi P, et al. J Control Release. 2018 Feb 28;272:159-168. doi: 10.1016/j.jconrel.2018.01.009. Epub 2018 Jan 19. J Control Release. 2018. PMID: 29355619 Review.
Cited by
- Aptamers as Smart Ligands for Targeted Drug Delivery in Cancer Therapy.
Wei Z, Zhou Y, Wang R, Wang J, Chen Z. Wei Z, et al. Pharmaceutics. 2022 Nov 22;14(12):2561. doi: 10.3390/pharmaceutics14122561. Pharmaceutics. 2022. PMID: 36559056 Free PMC article. Review. - Sequential Drug Delivery in Targeted Cancer Therapy.
Yu H, Ning N, Meng X, Chittasupho C, Jiang L, Zhao Y. Yu H, et al. Pharmaceutics. 2022 Mar 5;14(3):573. doi: 10.3390/pharmaceutics14030573. Pharmaceutics. 2022. PMID: 35335949 Free PMC article. Review. - Engineered exosomes from different sources for cancer-targeted therapy.
Zhang M, Hu S, Liu L, Dang P, Liu Y, Sun Z, Qiao B, Wang C. Zhang M, et al. Signal Transduct Target Ther. 2023 Mar 15;8(1):124. doi: 10.1038/s41392-023-01382-y. Signal Transduct Target Ther. 2023. PMID: 36922504 Free PMC article. Review. - Pharmaceutical Aspects of Nanocarriers for Smart Anticancer Therapy.
Hwang SR, Chakraborty K, An JM, Mondal J, Yoon HY, Lee YK. Hwang SR, et al. Pharmaceutics. 2021 Nov 5;13(11):1875. doi: 10.3390/pharmaceutics13111875. Pharmaceutics. 2021. PMID: 34834290 Free PMC article. Review. - Normal breast epithelial MCF-10A cells to evaluate the safety of carbon dots.
Vale N, Silva S, Duarte D, Crista DMA, Pinto da Silva L, Esteves da Silva JCG. Vale N, et al. RSC Med Chem. 2020 Dec 10;12(2):245-253. doi: 10.1039/d0md00317d. eCollection 2021 Mar 4. RSC Med Chem. 2020. PMID: 34046613 Free PMC article.
References
- Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev. 2003;55:329–47. - PubMed
- Davis ME, Chen Z, Shin DM. Nanoparticle therapeutics: An emerging treatment modality for cancer. Nat Rev Drug Discovery. 2008;7:771–82. - PubMed
- Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev. 2004;56:1649–59. - PubMed
- Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces. 2010;75:1–18. - PubMed
- Rivera E. Current status of liposomal anthracycline therapy in metastatic breast cancer. Clin Breast Cancer. 2003;4 Suppl 2:S76–83. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources